As CAR-T Therapies Move Into Earlier Lines, Best Uses Begin To Come Into Focus

Yescarta, Breyanzi Second-Line LBCL Approvals Expected Soon

Cost, logistics and safety could limit use of CAR-T therapies in first- and second-line treatment of hematologic malignancies, but for some patients there are clear benefits over standards of care.

Double escalator going up
CAR-T therapies are moving up from third-line or later into second-line and earlier settings • Source: Alamy

Chimeric antigen receptor T-cell (CAR-T) therapies have been a welcome addition to the treatment paradigm for patients with relapsed and refractory multiple myeloma and large B-cell lymphoma (LBCL) who have gone through several prior rounds of treatment and run out of good options. But within the next few months CAR-T therapies may take their first steps into earlier lines of treatment, raising the question of how physicians will adapt to use of these complex and costly treatments in new settings.

Gilead Sciences, Inc. is slated to get a decision from the US Food and Drug Administration by 1 April...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D